FDA approves New breast cancer drug

IBRANCE is targeted for post-menopausal women with advanced disease

IBRANCE® (palbociclib) is the first and only FDA-approved medication in a new class of treatment for postmenopausal women with ER+/HER2- metastatic breast cancer.




Pfizer's IBRANCE (palbociclib) inhibits molecules that play a role in the growth of cancer cells. It is intended for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have not yet received endocrine-based therapy, the FDA said.



IBRANCE is taken in combination with letrozole, a commonly used hormone therapy. 

A combination of IBRANCE with LETROZOLE delayed disease progression 2X longer than letrozole alone. 

Common side effects of IBRANCE:

Low white and red blood cell counts, fatigue, nausea, upper respiratory infection, diarrhea, vomiting, hair loss, inflammation of the lining of the mouth, decreased appetite, nosebleeds, and damage to the nerves in the extremities


To know more about ER+/HER2- METASTATIC BREAST CANCER: Wait till next week..for more updates :-)

Comments


  1. I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
    liver already present. I started on antiviral medications which
    reduced the viral load initially. After a couple of years the virus
    became resistant. I started on HEPATITIS B Herbal treatment from
    ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
    treatment totally reversed the virus. I did another blood test after
    the 6 months long treatment and tested negative to the virus. Amazing
    treatment! This treatment is a breakthrough for all HBV carriers.

    ReplyDelete

Post a Comment

Popular posts from this blog

FUNGAL DISEASES- solution CLOTRIMAZOLE

WORLD MENTAL HEALTH DAY 2019

ZIKA VIRUS : 4 LAKHS PEOPLE AFFECTED